The vaccine and a dominant variant may not match this year, which combined with low vaccine rates could make for a severe flu ...
The new trial, funded by Pfizer, compared the company’s mRNA shot to Fluzone, one of the most widely used seasonal flu ...
The mRNA platform offers the advantage of faster vaccine production, which could allow more time to decide on which flu strains to cover.
The experimental mRNA vaccine prevented 60% to 67% of flu infections, while the conventional vaccine prevented 44% to 54% of ...
Pfizer has released the full data from its phase 3 trial of an mRNA flu vaccine candidate, with the potential new shot demonstrating 34.5% greater efficacy compared to a control vaccine. | Pfizer has ...
Mutations to some H3N2 strains might be mismatched to the current flu vaccine, but doctors explain why it’s still a good idea ...
15hon MSN
Fredericton pharmacist encourages flu shot, even if vaccine may be mismatch for evolving strain
A Fredericton-based pharmacist says people are still showing up to get vaccinated for influenza, despite recent news that ...
As flu season ramps up and COVID and RSV cases continue to circulate, many people are unsure which vaccines to get — and when ...
Study shows high-dose vaccines work better for older adults while cell-based versions benefit younger people as respiratory ...
MedPage Today on MSN
mRNA Flu Vaccine Tops Standard Shot in Trial
For people younger than 65, U.S.-licensed flu vaccines had an estimated effectiveness of 44% to 54% that season. Among those ...
Flu vaccines are crucial tools in protecting public health by reducing the risk of influenza illness and its complications.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results